Intravitreal Sirolimus for the Treatment of Geographic Atrophy: Results of a Phase I/II Clinical Trial [Clinical Trials]

Conclusions.
While paralesional FAF changes and rapid retinal thinning observed are potentially part of the natural course of GA, they may possibly be related to treatment. No general evidence of anatomical or functional benefit was detected in treated eyes. Further data on intravitreal sirolimus for GA treatment will be available from a larger phase II trial. (ClinicalTrials.gov number, NCT01445548.)

Source: Investigative Ophthalmology - January 13, 2015 Category: Opthalmology Authors: Petrou, P. A., Cunningham, D., Shimel, K., Harrington, M., Hammel, K., Cukras, C. A., Ferris, F. L., Chew, E. Y., Wong, W. T. Tags: Clinical Trials Source Type: research